Compare ARK Genomic Revolution ETF (ARKG) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs D Wave Quantum Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while D Wave Quantum Inc trades at $19.89 (market cap $7.44B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | QBTS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $44.78 |
52-Week Low | $23.09 | $12.98 |
Market Cap | — | $7.44B |
Enterprise Value | — | $6.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
D-Wave Quantum (QBTS) trades at $20.08, down 5.1% today amid bearish technical signals. The stock shows extreme valuation metrics with P/S of 551.27 and negative profitability, though analyst consensus remains unanimously bullish with a $39.86 price target representing 99% upside. Recent IDC MarketScape recognition and government grants highlight technological progress, but substantial cash burn and negative margins pose fundamental challenges.
While analyst optimism and quantum computing's long-term potential offer speculative appeal, QBTS faces significant execution risks with negative earnings, high cash burn, and competitive threats. The stock's current technical weakness near key support at $20 suggests near-term pressure, making it suitable only for risk-tolerant investors betting on quantum commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
